EFFECTS OF TREATMENT ON AIRWAY DYNAMICS AND RESPIRATORY MUSCLE STRENGTH IN PARKINSONS-DISEASE

被引:70
作者
DEBRUIN, PFC
DEBRUIN, VMS
LEES, AJ
PRIDE, NB
机构
[1] HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,DIV RESP,LONDON W12 0NN,ENGLAND
[2] UNIV COLL & MIDDX HOSP,SCH MED,DEPT NEUROL,LONDON,ENGLAND
来源
AMERICAN REVIEW OF RESPIRATORY DISEASE | 1993年 / 148卷 / 06期
关键词
D O I
10.1164/ajrccm/148.6_Pt_1.1576
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
To investigate how treatment can affect airway dynamics and respiratory muscle strength in Parkinson's disease (PD), we assessed maximum effort inspiratory and expiratory mouth pressures (MIP and MEP), oscillatory impedance, and maximum expiratory and inspiratory flow-volume curves (MEFV and MIFV) in 10 patients (8 male and 2 female; mean age 51 +/- 5.3 yr, SD) after temporary interruption of antiparkinsonian therapy (off) and during continuous subcutaneous infusion of a direct stimulant of dopamine receptors, apomorphine (on). Treatment improved neurologic scores (off 25 +/- 5, on 9 +/- 5, modified Webster scale, p < 0.001), MEP (off 45 +/- 25, on 63 +/- 29 cm H2O, p = 0.003), and peak inspiratory flow (PIF; off 3.83 +/- 1.6, on 4.37 +/- 1.7 L/s, p = 0.028). Maximum inspiratory pressure was very low off treatment(-25 +/- 16 cm H2O) and improved moderately with apomorphine (-33 +/- 17 cm H2O) (p = 0.064). Total respiratory resistance during tidal breathing was normal in 9 patients both off and on treatment despite, in some cases, dramatic changes in MEFV and MIFV curves. These results suggest that abnormalities of the flow-volume curves may be due to problems in the rapid activation and coordination of contraction of upper airways and chest wall muscles during forced maneuvers, which is improved by apomorphine treatment.
引用
收藏
页码:1576 / 1580
页数:5
相关论文
共 19 条
[1]  
ARMITAGE P, 1987, STATISTICAL METHODS
[2]   MAXIMAL EXPIRATORY AND INSPIRATORY FLOW-VOLUME CURVES IN PARKINSONS-DISEASE [J].
BOGAARD, JM ;
HOVESTADT, A ;
MEERWALDT, J ;
VANDERMECHE, FGA ;
STIGT, J .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1989, 139 (03) :610-614
[3]   PARKINSONS-DISEASE - MANAGEMENT [J].
CLOUGH, CG .
LANCET, 1991, 337 (8753) :1324-1327
[4]   MORTALITY AND CAUSES OF DEATH IN IDIOPATHIC PARKINSONS-DISEASE - RESULTS FROM THE ABERDEEN WHOLE POPULATION STUDY [J].
EBMEIER, KP ;
CALDER, SA ;
CRAWFORD, JR ;
STEWART, L ;
BESSON, JAO ;
MUTCH, WJ .
SCOTTISH MEDICAL JOURNAL, 1990, 35 (06) :173-175
[5]  
ESTENNE M, 1984, NEW ENGL J MED, V311, P1516
[6]  
GARDNER WN, 1986, ADV NEUROL, V45, P271
[7]   PARKINSONISM - ONSET PROGRESSION AND MORTALITY [J].
HOEHN, MM ;
YAHR, MD .
NEUROLOGY, 1967, 17 (05) :427-&
[8]   LEVODOPA PERIPHERAL PHARMACOKINETICS AND DURATION OF MOTOR RESPONSE IN PARKINSONS-DISEASE [J].
KEMPSTER, PA ;
FRANKEL, JP ;
BOVINGDON, M ;
WEBSTER, R ;
LEES, AJ ;
STERN, GM .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1989, 52 (06) :718-723
[9]   NEW METHOD TO DETERMINE FREQUENCY-CHARACTERISTICS OF RESPIRATORY SYSTEM [J].
LANDSER, FJ ;
NAGELS, J ;
DEMEDTS, M ;
BILLIET, L ;
VANDEWOESTIJNE, KP .
JOURNAL OF APPLIED PHYSIOLOGY, 1976, 41 (01) :101-106
[10]  
LILKER ES, 1968, CAN MED ASSOC J, V99, P752